Matthew Riddle, MD

  • Degrees:
    MD: Harvard Medical School, Boston, 1964
  • Residency:
    Medicine, Rush-Presbyterian-St. Luke`s Medical Center, Chicago
  • Fellowship:
    Endocrinology, Rush-Presbyterian-St. Luke`s Medical Center, Chicago; Endocrinology, University of Washington, Seattle

 

  • Biosketch:
    Dr. Riddle`s clinical area of focus is in the treatment of diabetes with the aim of preventing or reducing its many disabling complications. "Diabetes, like most chronic illnesses, requires both standardized forms of treatment and individualization of care when standard methods fail," said Riddle, who heads OHSU`s Section of Diabetes. He is currently engaged in clinical trials called Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM), and Action to Control Cardiovascular Outcomes in Diabetes (ACCORD).
  • Recent Publications:

    Riddle MC. Timely initiation of basal insulin. Am J Med 2004;116(3A): 3S-9S.

    Ahmann A, Riddle MC. What to do when two oral agents fail to control type 2 diabetes - A matter of opinion or a matter of fact? (Editorial) Am J Med 2004;116: 276-8.

    Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 Nov;26(11):3080-6.

    Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide? J Clin Endocrinol Metab. 2003 Feb;88(2):528-30.

    Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S42-9.

    Ahmann AJ, Riddle MC. Current oral agents for type 2 diabetes. Many options, but which to choose when? Postgrad Med. 2002 May;111(5):32-4, 37-40, 43-6.

    Janka HU, Plewe G, Riddle MC, et al. Comparision of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28: 254-259.